Viridian Therapeutics, Inc. (VRDN)

Viridian Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	70.85	0.3	0.31	1.77	2.96
Revenue Growth (YoY)	23359.93%	-3.82%	-82.28%	-40.20%	182.19%
Gross Profit	70.85	0.3	0.31	1.77	2.96
Selling, General & Admin	95.32	61.08	95	35.18	25.81
Research & Development	338.93	238.25	159.77	100.89	56.89
Total Operating Expenses	434.24	299.34	254.76	136.08	82.69
Operating Income	-363.4	-299.04	-254.45	-134.3	-79.73
Interest Income	27.4	31.6	18.24	4.92	0.32
Interest Expense	-4.95	-2.2	-1.33	-0.49	-0
Other Non-Operating Income (Expense)	-1.66	-0.31	-0.19	4.43	0.32
Total Non-Operating Income (Expense)	20.79	29.09	16.72	8.86	0.63
Pretax Income	-342.6	-269.95	-237.73	-125.44	-79.1
Net Income	-342.6	-269.95	-237.73	-129.87	-79.41
Net Income to Common	-342.6	-269.95	-237.73	-129.87	-79.41
Shares Outstanding (Basic)	85	68	45	32	12
Shares Outstanding (Diluted)	85	68	45	32	12
Shares Change (YoY)	24.92%	51.68%	39.48%	169.22%	235.07%
EPS (Basic)	-3.32	-3.07	-3.91	-2.71	-6.66
EPS (Diluted)	-3.32	-3.07	-3.91	-2.71	-6.66
Free Cash Flow	-276.89	-232.83	-185.07	-185.07	-94.64
Free Cash Flow Per Share	-3.27	-3.43	-4.14	-5.77	-7.94
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-512.91%	-99018.21%	-81035.03%	-7579.23%	-2690.79%
Profit Margin	-483.57%	-89387.09%	-75711.46%	-7329.23%	-2680.16%
FCF Margin	-390.81%	-77096.03%	-58938.85%	-10444.02%	-3193.89%
EBITDA	-362.94	-298.5	-253.93	-133.78	-79.47
EBITDA Margin	-512.27%	-98839.40%	-80868.79%	-7549.77%	-2682.18%
EBIT	-363.4	-299.04	-254.45	-134.3	-79.73
EBIT Margin	-512.91%	-99018.21%	-81035.03%	-7579.23%	-2690.79%

Updated Feb 26, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q